eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2015-01-20 1 1 243 246 365 article Amit K. Dutta 1 N. Ganesh 1 C. S. Senthilkumar 1 N. K. Sah 2 Department of Research, Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal. School of Biotechnology, Rajiv Gandhi Technical University, Bhopal. Chronic Myeloid leukemia (CML) is a blood cancer of myeloid progenitors initiated with a triphasic absolutely curable with a targeted gene drug Imatinib mesylate. This study was conducted to reveal the effectiveness of Imatinib mesylate in 20 CML patients subjected with a follow – up of 9 months to evaluate their remission of the disease status. Complete hematological and Cytogenetic analysis was performed to find out the response of Imatinib mesylate against CML in every follow – up. Majority of the CML patients had showed a positive response in decreased level of abnormal cell proliferation and loss of Philadelphia positive chromosome(Ph+ve) in their profile. Our research evidenced a potential activity of Imatinib mesylate as a targeted gene therapy drug against CML. https://biomedpharmajournal.org/vol1no1/longterm-follow-up-of-cml-cases-with-imatinib-induction-a-hematological-and-cytogenetic-based-report/ Chronic Myeloid Leukemia Imatinib Induction Long term follow – up studies